A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...

A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...

A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

Living with IPF has brought many emotional ups and downs for columnist Sam Kirton, and recent events have caused him to hit ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Idiopathic pulmonary fibrosis (IPF) is when the lungs become scarred, and breathing becomes increasingly difficult. Damage to ...

Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...